TLSA — Tiziana Life Sciences Cashflow Statement
0.000.00%
- $133.17m
- $132.22m
Annual cashflow statement for Tiziana Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | Final | Final | Final |
Net Income/Starting Line | -10 | -28.3 | -26.7 | -15.4 | -17.2 |
Depreciation | |||||
Non-Cash Items | 1.66 | 16.6 | 4.11 | -3.6 | 3.03 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.31 | -0.294 | 0.642 | -0.674 | -1.58 |
Change in Accounts Receivable | |||||
Change in Accounts Payable | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -6.79 | -11.9 | -21.8 | -19.6 | -15.7 |
Capital Expenditures | -0.004 | -0.127 | -0.022 | 0 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0 | — | 0.152 | -4 | -1.25 |
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.004 | -0.127 | 0.13 | -4 | -1.25 |
Financing Cash Flow Items | 0 | -4.02 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.68 | 73.7 | -0.023 | -0.055 | 0.04 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -5.12 | 61.6 | -23.6 | -24.1 | -16.9 |